Isabel Gonzalez-Alvarez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3202185/publications.pdf

Version: 2024-02-01

105 papers	2,484 citations	201674 27 h-index	265206 42 g-index
113 all docs	113 docs citations	113 times ranked	3240 citing authors

#	Article	IF	Citations
1	PAMPAâ€"a drug absorption in vitro model. European Journal of Pharmaceutical Sciences, 2004, 21, 429-441.	4.0	187
2	Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B Coculture Models To Predict Intestinal and Colonic Permeability Compared to Caco-2 Monoculture. Molecular Pharmaceutics, 2017, 14, 1264-1270.	4.6	123
3	Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. Journal of Medicinal Chemistry, 2015, 58, 5825-5841.	6.4	88
4	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir. Journal of Pharmaceutical Sciences, 2008, 97, 5061-5073.	3.3	79
5	Provisional Classification and in Silico Study of Biopharmaceutical System Based on Caco-2 Cell Permeability and Dose Number. Molecular Pharmaceutics, 2013, 10, 2445-2461.	4.6	78
6	In Silico Prediction of Cacoâ€2 Cell Permeability by a Classification QSAR Approach. Molecular Informatics, 2011, 30, 376-385.	2.5	76
7	In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approaches. International Journal of Pharmaceutics, 2015, 480, 1-7.	5.2	63
8	Giardiasis: Characteristics, Pathogenesis and New Insights About Treatment. Current Topics in Medicinal Chemistry, 2018, 18, 1287-1303.	2.1	58
9	In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model. Journal of Pharmaceutical Sciences, 2015, 104, 3136-3145.	3.3	57
10	A topological substructural approach for the prediction of P-glycoprotein substrates. Journal of Pharmaceutical Sciences, 2006, 95, 589-606.	3.3	53
11	Segmental-dependent permeability throughout the small intestine following oral drug administration: Single-pass vs. Doluisio approach to in-situ rat perfusion. International Journal of Pharmaceutics, 2016, 515, 201-208.	5.2	46
12	Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 174-183.	4.3	45
13	Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS) Tj ETQq1 1 0.784314 rgBT /Overl Journal of Pharmaceutical Sciences, 2018, 115, 258-269.	4.0	43
14	New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy. International Journal of Molecular Sciences, 2020, 21, 6502.	4.1	43
15	The Use of Ruleâ€Based and QSPR Approaches in ADME Profiling: A Case Study on Caco-2 Permeability. Molecular Informatics, 2013, 32, 459-479.	2.5	42
16	Ionic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System. Biomacromolecules, 2018, 19, 1294-1304.	5.4	41
17	Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: New approaches for inflammatory bowel diseases treatment. Journal of Controlled Release, 2018, 281, 58-69.	9.9	39
18	Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. Xenobiotica, 2005, 35, 1067-1088.	1.1	35

#	Article	IF	Citations
19	Recent developments in cancer therapy and diagnosis. Journal of Pharmaceutical Investigation, 2020, 50, 349-361.	5.3	35
20	Evaluation of the intestinal permeability of rosemary (Rosmarinus officinalis L.) extract polyphenols and terpenoids in Caco-2 cell monolayers. PLoS ONE, 2017, 12, e0172063.	2.5	35
21	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. International Journal of Molecular Sciences, 2019, 20, 1606.	4.1	32
22	Variability of permeability estimation from different protocols of subculture and transport experiments in cell monolayers. Journal of Pharmacological and Toxicological Methods, 2015, 71, 21-32.	0.7	31
23	Phenolic compounds in rosemary as potential source of bioactive compounds against colorectal cancer: In situ absorption and metabolism study. Journal of Functional Foods, 2017, 33, 202-210.	3.4	30
24	In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation within vitro results. Biopharmaceutics and Drug Disposition, 2007, 28, 229-239.	1.9	29
25	Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as bloodâ€“brain barrier in vitro model. European Journal of Pharmaceutical Sciences, 2011, 42, 290-299.	4.0	29
26	Ion-pair strategy for enabling amifostine oral absorption: Rat in situ and in vivo experiments. European Journal of Pharmaceutical Sciences, 2013, 49, 499-504.	4.0	28
27	Permeability Study of Polyphenols Derived from a Phenolic-Enriched Hibiscus sabdariffa Extract by UHPLC-ESI-UHR-Qq-TOF-MS. International Journal of Molecular Sciences, 2015, 16, 18396-18411.	4.1	28
28	Investigating drug absorption from the colon: Single-pass vs. Doluisio approaches to in-situ rat large-intestinal perfusion. International Journal of Pharmaceutics, 2017, 527, 135-141.	5.2	28
29	Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System. Pharmaceutics, 2019, 11, 567.	4.5	27
30	Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. Molecular Pharmaceutics, 2015, 12, 3167-3174.	4.6	26
31	In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. Molecular Pharmaceutics, 2018, 15, 2307-2315.	4.6	26
32	PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. European Journal of Pharmaceutical Sciences, 2018, 115, 119-125.	4.0	25
33	Drug penetration across the bloodâ€“brain barrier: an overview. Therapeutic Delivery, 2010, 1, 535-562.	2.2	24
34	Kinetic modelling of the intestinal transport of sarafloxacin. Studiesin situin rat andin vitroin Caco-2 cells. Journal of Drug Targeting, 2005, 13, 199-212.	4.4	23
35	An Exploratory Study of Two Caco-2 Cell Models for Oral Absorption: A Report on Their Within-laboratory and Between-laboratory Variability, and Their Predictive Capacity. ATLA Alternatives To Laboratory Animals, 2010, 38, 367-386.	1.0	23
36	Validation of phenol red versus gravimetric method for water reabsorption correction and study of gender differences in Doluisioâ€™s absorption technique. European Journal of Pharmaceutical Sciences, 2014, 62, 105-110.	4.0	23

#	Article	IF	Citations
37	Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Ratâ€"Biophysical Model and Predictions Based on Caco-2. Pharmaceutical Research, 2018, 35, 2.	3.5	23
38	Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Linear kinetics (I). European Journal of Pharmaceutical Sciences, 2009, 36, 137-146.	4.0	22
39	Hydrogels: an interesting strategy for smart drug delivery. Therapeutic Delivery, 2013, 4, 157-160.	2.2	22
40	A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. European Journal of Medicinal Chemistry, 2014, 83, 366-373.	5.5	22
41	Unexpected findings at imaging: Predicting frequency in various types of studies. European Journal of Radiology, 2010, 74, 269-274.	2.6	21
42	Comparison of segmental-dependent permeability in human and in situ perfusion model in rat. European Journal of Pharmaceutical Sciences, 2017, 107, 191-196.	4.0	21
43	QSPR in Oral Bioavailability: Specificity or Integrality?. Mini-Reviews in Medicinal Chemistry, 2012, 12, 534-550.	2.4	20
44	Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Bloodâ€"Brain Barrier. Molecular Pharmaceutics, 2013, 10, 3822-3831.	4.6	19
45	In vitro model for predicting the access and distribution of drugs in the brain using hCMEC/D3 cells. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 120-126.	4.3	19
46	Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics. European Journal of Pharmaceutical Sciences, 2009, 36, 147-156.	4.0	18
47	Modified Nonsink Equation for Permeability Estimation in Cell Monolayers: Comparison with Standard Methods. Molecular Pharmaceutics, 2014, 11, 1403-1414.	4.6	18
48	Assessment of the Regulatory Methods for the Comparison of Highly Variable Dissolution Profiles. AAPS Journal, 2016, 18, 1550-1561.	4.4	18
49	Gated Mesoporous Silica Nanocarriers for a â€œTwo-Stepâ€•Targeted System to Colonic Tissue. Molecular Pharmaceutics, 2017, 14, 4442-4453.	4.6	18
50	Determination of intestinal permeability using in situ perfusion model in rats: Challenges and advantages to BCS classification applied to digoxin. International Journal of Pharmaceutics, 2018, 551, 148-157.	5.2	18
51	Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. British Journal of Clinical Pharmacology, 2018, 84, 2231-2241.	2.4	18
52	Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease. Molecular Pharmaceutics, 2019, 16, 2418-2429.	4.6	18
53	Semisynthesis, Cytotoxic Activity, and Oral Availability of New Lipophilic 9-Substituted Camptothecin Derivatives. ACS Medicinal Chemistry Letters, 2013, 4, 651-655.	2.8	17
54	Tubulin acetylation promoting potency and absorption efficacy of deacetylase inhibitors. British Journal of Pharmacology, 2015, 172, 829-840.	5.4	17

#	Article	IF	Citations
55	Development of an ion-pair to improve the colon permeability of a low permeability drug: Atenolol. European Journal of Pharmaceutical Sciences, 2016, 93, 334-340.	4.0	17
56	Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. Pharmaceutics, 2019, 11, 122.	4.5	17
57	Candesartan Cilexetil In Vitroâ€"In Vivo Correlation: Predictive Dissolution as a Development Tool. Pharmaceutics, 2020, 12, 633.	4.5	17
58	Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019. Pharmaceutics, 2020, 12, 316.	4.5	17
59	A topological-substructural molecular design (TOPS-MODE) approach to determining pharmacokinetics and pharmacological properties of 6-fluoroquinolone derivatives. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 197-206.	4.3	16
60	Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells. Journal of Microencapsulation, 2008, 25, 561-568.	2.8	15
61	In vitroâ€"in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 65-75.	1.6	15
62	Drug gastrointestinal absorption in rat: Strain and gender differences. European Journal of Pharmaceutical Sciences, 2015, 78, 198-203.	4.0	15
63	Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. Pharmaceutics, 2020, 12, 295.	4.5	15
64	Computer simulations for bioequivalence trials: Selection of analyte in BCS drugs with first-pass metabolism and two metabolic pathways. European Journal of Pharmaceutical Sciences, 2010, 41, 716-728.	4.0	14
65	Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2008, 366, 3599-3617.	3.4	13
66	Oral controlled release dosage forms: dissolution versus diffusion. Expert Opinion on Drug Delivery, 2020, 17, 791-803.	5.0	13
67	Management of patients with incidental findings in imaging tests: a large prospective single-center study. Clinical Imaging, 2014, 38, 249-254.	1.5	12
68	Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics, 2020, 12, 988.	4.5	12
69	Exploring different strategies for imbalanced ADME data problem: case study on Caco-2 permeability modeling. Molecular Diversity, 2016, 20, 93-109.	3.9	11
70	Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug. International Journal of Pharmaceutics, 2019, 557, 36-42.	5.2	11
71	Lung cancer risk and cancer-specific mortality in subjects undergoing routine imaging test when stratified with and without identified lung nodule on imaging study. European Radiology, 2015, 25, 3518-3527.	4.5	10
72	Preclinical models for colonic absorption, application to controlled release formulation development. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 130, 247-259.	4.3	10

#	Article	IF	Citations
73	Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products. Pharmaceutics, 2019, 11, 663.	4.5	10
74	A differential equation based modelling approach to predict supersaturation and in vivo absorption from in vitro dissolution-absorption system (idas2) data. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 1-12.	4.3	9
75	Unique pharmacology of KAR-2, a potential anti-cancer agent: Absorption modelling and selective mitotic spindle targeting. European Journal of Pharmaceutical Sciences, 2009, 36, 11-19.	4.0	8
76	Population pharmacokinetic model of lithium and drug compliance assessment. European Neuropsychopharmacology, 2016, 26, 1868-1876.	0.7	8
77	Surfactant-Triggered Molecular Gate Tested on Different Mesoporous Silica Supports for Gastrointestinal Controlled Delivery. Nanomaterials, 2020, 10, 1290.	4.1	8
78	Effect of excipients on oral absorption process according to the different gastrointestinal segments. Expert Opinion on Drug Delivery, 2021, 18, 1005-1024.	5.0	8
79	Effect of Common Excipients on Intestinal Drug Absorption in Wistar Rats. Molecular Pharmaceutics, 2020, 17, 2310-2318.	4.6	8
80	Intestinal Permeability of Î²-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 795-806.	1.6	7
81	In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium. Pharmaceutics, 2020, 12, 558.	4.5	7
82	An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics, 2021, 13, 507.	4.5	7
83	Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system. ADMET and DMPK, 2021, 9, 23-39.	2.1	7
84	An Innovative Formulation Based on Nanostructured Lipid Carriers for Imatinib Delivery: Pre-Formulation, Cellular Uptake and Cytotoxicity Studies. Nanomaterials, 2022, 12, 250.	4.1	7
85	Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. European Journal of Pharmaceutical Sciences, 2015, 74, 86-94.	4.0	6
86	Enhancing Oral Absorption of Î²-Lapachone: Progress Till Date. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 1-10.	1.6	6
87	Impact on intestinal permeability of pediatric hyperosmolar formulations after dilution: Studies with rat perfusion method. International Journal of Pharmaceutics, 2019, 557, 154-161.	5.2	6
88	Effect of thickener on disintegration, dissolution and permeability of common drug products for elderly patients. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 168-176.	4.3	6
89	Differences in the clinical management of women and men after detection of a solitary pulmonary nodule in clinical practice. European Radiology, 2020, 30, 4390-4397.	4.5	6
90	Two-step in vitro-in vivo correlations: Deconvolution and convolution methods, which one gives the best predictability? Comparison with one-step approach. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 185-197.	4.3	6

#	Article	IF	Citations
91	A new mathematical approach for the estimation of the AUC and its variability under different experimental designs in preclinical studies. Pharmaceutical Statistics, 2012, 11, 14-23.	1.3	5
92	Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. Xenobiotica, 2013, 43, 745-754.	1.1	5
93	Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation. Pharmaceutics, 2021, 13, 272.	4.5	5
94	Lactose-Gated Mesoporous Silica Particles for Intestinal Controlled Delivery of Essential Oil Components: An In Vitro and In Vivo Study. Pharmaceutics, 2021, 13, 982.	4.5	5
95	Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs. Pharmaceutics, 2018, 10, 213.	4.5	4
96	Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat. Pharmaceutics, 2021, 13, 1402.	4.5	4
97	The Fate of Patients with Solitary Pulmonary Nodules: Clinical Management and Radiation Exposure Associated. PLoS ONE, 2016, 11, e0158458.	2.5	4
98	New In Vitro Methodology for Kinetics Distribution Prediction in the Brain. An Additional Step towards an Animal-Free Approach. Animals, 2021, 11, 3521.	2.3	4
99	pH-Dependent Molecular Gate Mesoporous Microparticles for Biological Control of Giardia intestinalis. Pharmaceutics, 2021, 13, 94.	4.5	3
100	How and Where Are Drugs Absorbed?. , 0, , 249-280.		3
101	Exploring the Predictive Power of the In Situ Perfusion Technique towards Drug Absorption: Theory, Practice, and Applications. Molecular Pharmaceutics, 2022, 19, 749-762.	4.6	3
102	Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients. European Journal of Pharmaceutical Sciences, 2015, 73, 57-63.	4.0	2
103	One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products. Pharmaceutics, 2021, 13, 690.	4.5	2
104	Eremantholide C from aerial parts of Lychnophora trichocarpha, as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination. DARU, Journal of Pharmaceutical Sciences, 2021, 29, 195-203.	2.0	1
105	Integration of In Silico, In Vitro and In Situ Tools for the Preformulation and Characterization of a Novel Cardio-Neuroprotective Compound during the Early Stages of Drug Development. Pharmaceutics, 2022, 14, 182.	4.5	0